The primary objective of this study is to evaluate the efficacy of BIIB067 when initiated in
presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated
neurofilament (NF). The secondary objectives of this study are to evaluate the safety and
tolerability of BIIB067 and to evaluate the effect of BIIB067 on pharmacodynamics
(PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of
clinically manifest amyotrophic lateral sclerosis (ALS).
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.